The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.

María Rivera Sánchez, Sophie E Mastenbroek, Shorena Janelidze, Pontus Tideman, Niklas Mattsson-Carlgren, Danielle Van Westen, Erik Stomrud, Oskar Hansson, Sebastian Palmqvist, Rik Ossenkoppele

BACKGROUND AND OBJECTIVES: Subjective cognitive decline (SCD) is a well-recognized risk state for developing mild cognitive impairment (MCI) and dementia. Optimal risk stratification for early interventions and clinical trial selection remains challenging. This study evaluates progression risk across multimodal biomarker profiles in SCD. METHODS: We conducted a longitudinal observational study including participants from the BioFINDER-1 and BioFINDER-2 cohorts with a baseline diagnosis of SCD, at least 1 follow-up visit, and available information on dementia progression. Baseline predictors included cognitive performance, RESULTS: A total of 469 participants with SCD (mean age 69.1 ± 7.1 years, 51.4% female) were included in the main sample. Eighty-four individuals progressed to dementia over 4.0 ± 2.1 years (66.7% AD dementia). Progressors were older and more frequently DISCUSSION: A clinically feasible multimodal approach combining cognitive assessment, plasma p-tau217, and

Read on ELI